Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial

Ahmanson-University of California, Los Angeles.

To compare the benefit of angiotensin-converting enzyme inhibition and direct vasodilation on the prognosis of advanced heart failure, 117 patients evaluated for cardiac transplantation who had severe symptoms and abnormal hemodynamic status at rest were randomized to treatment with either captopril or hydralazine plus isosorbide dinitrate (Hy-C Trial). Comparable hemodynamic effects of the two regimens were sought by titrating vasodilator doses to match the hemodynamic status achieved with nitroprusside and diuretic agents, attempting to achieve a pulmonary capillary wedge pressure of 15 mm Hg and a systemic vascular resistance of 1,200 dynes.s.cm-5. Treatment with the alternate vasodilator was started because of poor hemodynamic response or side effects (40% of patients in the captopril group and 22% in the hydralazine group). Adequate hemodynamic response in patients with a serum sodium level less than 135 mg/dl was more likely with hydralazine than with captopril (71% vs. 33%, p = 0.04). Isosorbide dinitrate was prescribed in 88% of the hydralazine-treated patients and 84% of the captopril-treated patients. The hemodynamic improvements from each regimen were equivalent. After 8 +/- 7 months of follow-up, the actuarial 1-year survival rate was 81% in the captopril-treated patients and 51% in the hydralazine-treated patients (p = 0.05). The improved survival with captopril resulted from a lower rate of sudden death, which occurred in only 3 of 44 captopril-treated patients compared with 17 of 60 hydralazine-treated patients (p = 0.01). In the subset of patients who continued treatment with the initial vasodilator, results were similar to those for the entire treatment group.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				H. E. Verdejo, P. F. Castro, R. Concepcion, M. A. Ferrada, M. A. Alfaro, M. E. Alcaino, C. C. Deck, and R. C. Bourge Comparison of a Radiofrequency-Based Wireless Pressure Sensor to Swan-Ganz Catheter and Echocardiography for Ambulatory Assessment of Pulmonary Artery Pressure in Heart Failure J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2375 - 2382. [Abstract] [Full Text] [PDF]

				C. Funck-Brentano Beta-blockade in CHF: from contraindication to indication Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C19 - C27. [Abstract] [Full Text] [PDF]

				The ESCAPE Investigators and ESCAPE Study Coordina Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: The ESCAPE Trial JAMA, October 5, 2005; 294(13): 1625 - 1633. [Abstract] [Full Text] [PDF]

				J. A. Reiffel Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S45 - S58. [Abstract] [PDF]

				K. Kalantar-Zadeh, K. C Abbott, A. K Salahudeen, R. D Kilpatrick, and T. B Horwich Survival advantages of obesity in dialysis patients Am. J. Clinical Nutrition, March 1, 2005; 81(3): 543 - 554. [Abstract] [Full Text] [PDF]

				H. Thai, J. Wollmuth, S. Goldman, and M. Gaballa Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2 Receptor J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1171 - 1178. [Abstract] [Full Text] [PDF]

				H. Montgomery, S. Humphries, and S. Danilov Is genotype or phenotype the better tool for investigating the role of ACE in human cardiovascular disease? Eur. Heart J., July 2, 2002; 23(14): 1083 - 1086. [Full Text] [PDF]

				W. Johnson, T. Omland, C. Hall, C. Lucas, O. L. Myking, C. Collins, M. Pfeffer, J.-L. Rouleau, and L. W. Stevenson Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failure J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1623 - 1629. [Abstract] [Full Text] [PDF]

				A. Nohria, E. Lewis, and L. W. Stevenson Medical Management of Advanced Heart Failure JAMA, February 6, 2002; 287(5): 628 - 640. [Abstract] [Full Text] [PDF]

				T. B. Horwich, G. C. Fonarow, M. A. Hamilton, W. R. MacLellan, M. A. Woo, and J. H. Tillisch The relationship between obesity and mortality in patients with heart failure J. Am. Coll. Cardiol., September 1, 2001; 38(3): 789 - 795. [Abstract] [Full Text] [PDF]

				A Ohlsson, S.H Kubo, D Steinhaus, D.T Connelly, S Adler, C Bitkover, R Nordlander, L Ryden, and T Bennett Continuous ambulatory monitoring of absolute right ventricular pressure and mixed venous oxygen saturation in patients with heart failure using an implantable haemodynamic monitor: results of a 1 year multicentre feasibility study Eur. Heart J., June 1, 2001; 22(11): 942 - 954. [Abstract] [PDF]

				P. Colson, F. Ryckwaert, and P. Coriat Renin Angiotensin System Antagonists and Anesthesia Anesth. Analg., November 1, 1999; 89(5): 1143 - 1143. [Full Text] [PDF]

				J C Vaile, J Fletcher, W A Littler, J H Coote, and J N Townend Angiotensin II modulates cardiovascular autonomic control in the absence of baroreflex loading Heart, August 1, 1998; 80(2): 127 - 133. [Abstract] [Full Text]

				British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and endorsed by the British Diabetic Association Joint British recommendations on prevention of coronary heart disease in clinical practice Heart, July 1, 1998; 80(90002): 1S - 29. [Full Text]

				P. Jaagosild, N. V. Dawson, C. Thomas, N. S. Wenger, J. Tsevat, W. A. Knaus, R. M. Califf, L. Goldman, H. Vidaillet, A. F. Connors Jr, et al. Outcomes of Acute Exacerbation of Severe Congestive Heart Failure: Quality of Life, Resource Use, and Survival Arch Intern Med, May 25, 1998; 158(10): 1081 - 1089. [Abstract] [Full Text] [PDF]

				V. S. Chekanov, S. Deshpande, and D. H. Schmidt CARDIOMYOPLASTY COMBINED WITH IMPLANTATION OF A CARDIOVERTER DEFIBRILLATOR J. Thorac. Cardiovasc. Surg., September 1, 1997; 114(3): 489 - 491. [Full Text]

				A. E. Steimle, L. W. Stevenson, C. Chelimsky-Fallick, G. C. Fonarow, M. A. Hamilton, J. D. Moriguchi, A. Kartashov, and J. H. Tillisch Sustained Hemodynamic Efficacy of Therapy Tailored to Reduce Filling Pressures in Survivors With Advanced Heart Failure Circulation, August 19, 1997; 96(4): 1165 - 1172. [Abstract] [Full Text]

				L. W. Stevenson, G. Couper, B. Natterson, G. Fonarow, M. A. Hamilton, M. Woo, and J. W. Creaser Target Heart Failure Populations for Newer Therapies Circulation, November 1, 1995; 92(9): 174 - 181. [Abstract] [Full Text]

				G. M. Eaton, R. J. Cody, E. Nunziata, and P. F. Binkley Early Left Ventricular Dysfunction Elicits Activation of Sympathetic Drive and Attenuation of Parasympathetic Tone in the Paced Canine Model of Congestive Heart Failure Circulation, August 1, 1995; 92(3): 555 - 561. [Abstract] [Full Text]

				J. N. Townend, M. Al-Ani, J. N. West, W. A. Littler, and J. H. Coote Modulation of Cardiac Autonomic Control in Humans by Angiotensin II Hypertension, June 1, 1995; 25(6): 1270 - 1275. [Abstract] [Full Text]

				L. Nascimben, J. Friedrich, R. Liao, P. Pauletto, A. C. Pessina, and J. S. Ingwall Enalapril Treatment Increases Cardiac Performance and Energy Reserve Via the Creatine Kinase Reaction in Myocardium of Syrian Myopathic Hamsters With Advanced Heart Failure Circulation, March 15, 1995; 91(6): 1824 - 1833. [Abstract] [Full Text]